ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

イバブラジン

Ivabradine

HCID 132999
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
155974-00-8
標準SMILES
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2
InChIKey
ACRHBAYQBXXRTO-OAQYLSRUSA-N
分子式
C27H36N2O5
平均分子量
468.6 g/mol
単同位体質量
468.26242225

概要

Ivabradine is a member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. It has a role as a cardiotonic drug. It is an aromatic ether, a benzazepine, a carbobicyclic compound and a tertiary amino compound. It is a conjugate base of an ivabradine(1+).

名称と識別子

優先名称
Ivabradine
IUPAC
3-[3-[[(7S)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
現地名
イバブラジン
英語名
Ivabradine
分子式
C27H36N2O5
分子量
468.59

名称と別名

Ivabradine155974-00-8S-16257IvabradinaS 162573H48L0LPZQDTXSID2048240s162573-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-oneCHEBI:85966(S)-3-(3-(((3,4-Dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one2H-3-Benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, (S)-
名称をさらに表示
イバブラジン3-[3-[N-[[(7S)-3,4-ジメトキシビシクロ[4.2.0]オクタ-1,3,5-トリエン-7-イル]メチル]-N-メチルアミノ]プロピル]-7,8-ジメトキシ-4,5-ジヒドロ-1H-3-ベンゾアゼピン-2(3H)-オン3-[3-({[(7S)-3,4-ジメトキシビシクロ[4.2.0]オクタ-1(6),2,4-トリエン-7-イル]メチル}(メチル)アミノ)プロピル]-7,8-ジメトキシ-2,3,4,5-テトラヒドロ-1H-3-ベンゾアゼピン-2-オン7,8-ジメトキシ-4,5-ジヒドロ-3-[3-[メチル[[(7S)-3,4-ジメトキシビシクロ[4.2.0]オクタ-1,3,5-トリエン-7-イル]メチル]アミノ]プロピル]-1H-3-ベンゾアゼピン-2(3H)-オン3-[3-[[[(7S)-3,4-ジメトキシビシクロ[4.2.0]オクタ-1,3,5-トリエン-7-イル]メチル]メチルアミノ]プロピル]-1,3,4,5-テトラヒドロ-7,8-ジメトキシ-2H-3-ベンゾアゼピン-2-オン

物性

構造計算による物性補完中

XLogP
2.4
極性表面積
60.5 Ų
水素結合供与体数
0
水素結合受容体数
6
回転可能結合数
10
重原子数
34
形式電荷
0
複雑度
663

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 6 件

Breast Feeding; Lactation; Milk, Human; Cardiovascular Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Endocrine DisruptorsPotential endocrine disrupting compound

物理化学的性質

沸点
626.9 · 626.9±55.0 °C(Predicted)
比重(密度)
1.146 · 1.146±0.06 g/cm3(Predicted)
酸解離定数(Pka)
8.77 · 8.77±0.50(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

HepatotoxicityIn large preregistration clinical trials, similar proportions of patients taking ivabradine as taking placebo developed ALT elevations [15% vs 17%] while ALT elevations above 5 times the upper limit of normal were uncommon [
Adverse EffectsThe most common adverse effects associated with ivabradine administration, according to the product label, include bradycardia, atrial fibrillation, hypertension, and phosphenes.
Toxicity SummarySigns and Symptoms of Overdose
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

化学と産業

薬理情報

ATC Code · 3 件

C01EB17

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding70% bound to plasma proteins.
Pharmacodynamics · 1 件

The funny channels (If) open during repolarization and close during depolarization, making ivabradine's activity dependent on heart rate or the closing and opening of the channels. Therefore ivabradine exhibits use-dependence and is more pharmacologically active at higher heart rates. Ivabradine exhibits a linear dose-dependent heart-rate lowering activity (bradycardic effect) until a maximum dose of 30-40mg. At higher doses, the concentration of ivabradine tends to plateau, reducing risk of serious sinus bradycardia. It has been shown that the metabolite of ivabradine lowers heart rate as well, contributing to ivabradine's overall effect.

Mechanism of Action · 1 件

Ivabradine lowers heart rate by selectively inhibiting If channels ("funny channels") in the heart in a concentration-dependent manner without affecting any other cardiac ionic channels (including calcium or potassium). Ivabradine binds by entering and attaching to a site on the channel pore from the intracellular side and disrupts If ion current flow, which prolongs diastolic depolarization, lowering heart rate. The If currents are located in the sinoatrial node and are the home of all cardiac pacemaker activity. Ivabradine therefore lowers the pacemaker firing rate, consequently lowering heart rate and reducing myocardial oxygen demand. This allows for an improved oxygen supply and therefore mitigation of ischemia, allowing for a higher exercise capacity and reduction in angina episodes.

Biological Half-Life2 hours.
Metabolism/Metabolites · 1 件

Ivabradine is extensively metabolized by oxidation in the gut and liver by cytochrome P450 3A4 enzyme. Its active metabolite, N-desmethylated derivative, is also metabolized by CYP 3A4. Ivabradine's affinity for CYP 3A4 is low, making it unlikely to affect the metabolism of other drugs; however potent inhibitors or inducers of CYP 3A4 may affect ivabradine's plasma concentration and pharmacodynamic effects and should not be co-administered.

関連反応

19 件
反応記録を作成
HRID 218987 の反応式
HRID 218987生成物として反応物として
HRID 420869 の反応式
HRID 420869生成物として
HRID 420870 の反応式
HRID 420870生成物として
HRID 423132 の反応式
HRID 423132生成物として
HRID 423133 の反応式
HRID 423133反応物として
HRID 423134 の反応式
HRID 423134生成物として
HRID 423135 の反応式
HRID 423135反応物として
HRID 523523 の反応式
HRID 523523反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
Ivabradine sulfate
Ivabridine –
Ivabradine API
Ivabradine USP/EP/BP
Ivabradine HCl Premix
N-desmethyl ivabridine-d6
Ivabradine(Hydrochloride form)
3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methyl-amino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one
Ivabradinum3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one3-(3-(((8S)-3,4-dimethoxy-8-bicyclo(4.2.0)octa-1,3,5-trienyl)methyl-methylamino)propyl)-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-oneRefChem:56735S162572S162602S 162572

データベース識別子

CAS
155974-00-8
PubChem CID
132999
DTXSID
DTXSID2048240
ChEMBL
CHEMBL471737
ChEBI
CHEBI:85966
UNII
3H48L0LPZQ
Nikkaji
J582.018I
FDA Pharmacological Classification · 6 件

3H48L0LPZQ

IVABRADINE

Established Pharmacologic Class [EPC] - Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker

Mechanisms of Action [MoA] - Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists

Ivabradine is a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker. The mechanism of action of ivabradine is as a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonist.

IVABRADINE

MeSH Pharmacological ClassificationAgents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Absorption, Distribution and Excretion · 4 件

It is recommended to take ivabradine with food to reduce variability in systemic exposure. Administration with food slows absorption by 1 hour, but increases systemic absorption by 20-30%. Ivabradine's oral bioavailability is about 40%.

Metabolites are equally excreted in feces and urine.

~100 L.

Total clearance is about 400ml/min; renal clearance about 70ml/min. About 4% is excreted unchanged in urine.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >75
応用分野 · 1 件

説明Ivabradine is a first selective and specific If inhibitor that was approved by EMEA in November for symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm. This is the first agent to lower heart rate by inhibiting the cardiac pacemaker If current. The compound was discovered and developed by Servier and is currently being marketed in Ireland.

上流・下流製品情報

上流原料

3H-3-Benzazepine-3-propanal, 1,2,4,5-tetrahydro-7,8-dimethoxy-2-oxo-(S)-(4,5-diMethoxy-1,2-dihydrocyclobutabenzen-1-yl)-N-MethylMethanaMine3-[3-[[[(7S)-3,4-DiMethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]Methyl]MethylaMino]propyl]-1,3-dihydro-7,8-diMethoxy-H-3-benzazepin-2-one
補足説明 · 1 件

定義ChEBI: A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Use (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure.